A Phase 1b/2a, Cross-over, Randomised, Double-blind, Placebo Controlled Study to Investigate the Safety and Pharmacodynamic Effects of GET 73 in Alcohol Dependent Subjects

Trial Profile

A Phase 1b/2a, Cross-over, Randomised, Double-blind, Placebo Controlled Study to Investigate the Safety and Pharmacodynamic Effects of GET 73 in Alcohol Dependent Subjects

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Sep 2017

At a glance

  • Drugs GET 73 (Primary)
  • Indications Alcohol withdrawal
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Acronyms SPAD
  • Sponsors CT Laboratories
  • Most Recent Events

    • 01 Sep 2017 Planned End Date changed from 1 Apr 2017 to 1 Nov 2017.
    • 01 Sep 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Nov 2017.
    • 12 Sep 2016 Planned End Date changed from 1 Jun 2016 to 1 Apr 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top